Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: Critical role in resistance to toll-like receptor 3-mediated apoptosis

Neoplasia

Volumn 10, Issue 11, 2008, Pages 1183-1194

  Friboulet, Luc ^a   Pioche Durieu, Catherine ^a   Rodriguez, Sandrine ^a   Valent, Alexander ^a   Souquère, Sylvie ^b   Ripoche, Hugues ^a   Khabir, Abdelmajid ^c   Sai, Wah Tsao ^d   Bosq, Jacques ^a   Kwok, Wai Lo ^e   Busson, Pierre ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT ANDRÉ LWOFF   (France)

^c UNIVERSITY OF SFAX   (Tunisia)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; PROTEIN DERIVATIVE; RMT 5265; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL FRACTIONATION; CELL FUNCTION; CELL GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVATION; EPITHELIUM CELL; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION;

EID: 55849099271     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08590     Document Type: Article

References (43)

1. Busson P, Keryer C, Ooka T, and Corbex M (2004). EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12 (8), 356-360.
2. Chang ET and Adami HO (2006). The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 15 (10), 1765-1777.
3. Fachiroh J, Schouten T, Hariwiyanto B, Paramita DK, Harijadi A, Haryana SM, Ng MH, and Middeldorp JM (2004). Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190 (1), 53-62.
4. Feng BJ, Jalbout M, Ayoub WB, Khyatti M, Dahmoul S, Ayad M, Maachi F, Bedadra W, Abdoun M, Mesli S, et al. (2007). Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer 121 (7), 1550-1555.
5. Lu SJ, Day NE, Degos L, Lepage V, Wang PC, Chan SH, Simons M, McKnight B, Easton D, Zeng Y, et al. (1990). Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature 346 (6283), 470-471.
6. Samanta M, Iwakiri D, Kanda T, Imaizumi T, and Takada K (2006). EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 25 (18), 4207-4214.
7. Ma BB and Chan AT (2006). Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma. Exp Rev Anticancer Ther 6 (3), 383-394.
8. Sbih-Lammali F, Clausse B, Ardila-Osorio H, Guerry R, Talbot M, Havouis S, Ferradini L, Bosq J, Tursz T, and Busson P (1999). Control of apoptosis in Epstein Barr virus-positive nasopharyngeal carcinoma cells: opposite effects of CD95 and CD40 stimulation. Cancer Res 59 (4), 924-930.
9. Tang KF, Tan SY, Chan SH, Chong SM, Loh KS, Tan LK, and Hu H (2001). A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum Pathol 32 (1), 42-49.
10. Hunter AM, LaCasse EC, and Korneluk RG (2007). The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12 (9), 1543-1568.
11. Vucic D and Fairbrother WJ (2007). The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13 (20), 5995-6000.
12. Altieri DC (2008). Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8 (1), 61-70.
13. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, et al. (2007). IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131 (4), 669-681.
14. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harran P, and Wang X (2007). Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12 (5), 445-456.
15. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 125 (7), 1253-1267.
16. Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, Ohki M, and Inazawa J (2001). Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res 61 (18), 6629-6634.
17. Conte D, Holcik M, Lefebvre CA, Lacasse E, Picketts DJ, Wright KE, and Korneluk RG (2006). Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol Cell Biol 26 (2), 699-708.
18. Kanzler H, Barrat FJ, Hessel EM, and Coffman RL (2007). Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 13 (5), 552-559.
19. Salaun B, Romero P, and Lebecque S (2007). Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol 37 (12), 3311-3318.
20. Huang B, Zhao J, Unkeless JC, Feng ZH, and Xiong H (2008). TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 27 (2), 218-224.
21. Han KJ, Su X, Xu LG, Bin LH, Zhang J, and Shu HB (2004). Mechanisms of the TRIF-induced interferon-stimulated response element and NF-kappaB activation and apoptosis pathways. J Biol Chem 279 (15), 15652-15661.
22. Salaun B, Coste I, Rissoan MC, Lebecque SJ, and Renno T (2006). TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 176 (8), 4894-4901.
23. Salaun B, Lebecque S, Matikainen S, Rimoldi D, and Romero P (2007). Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res 13 (15 Pt. 1), 4565-4574.
24. Busson P, Zhang Q, Guillon JM, Gregory CD, Young LS, Clausse B, Lipinski M, Rickinson AB, and Tursz T (1992). Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells. Int J Cancer 50 (6), 863-867.
25. Vicat JM, Ardila-Osorio H, Khabir A, Brezak MC, Viossat I, Kasprzyk P, Jlidi R, Opolon P, Ooka T, Prevost G, et al. (2003). Apoptosis and TRAF-1 cleavage in Epstein-Barr virus-positive nasopharyngeal carcinoma cells treatedwith doxorubicin combined with a farnesyl-transferase inhibitor. Biochem Pharmacol 65 (3), 423-433.
26. Hui AB, Cheung ST, Fong Y, Lo KW, and Huang DP (1998). Characterization of a new EBV-associated nasopharyngeal carcinoma cell line. Cancer Genet Cytogenet 101 (2), 83-88.
27. Tsao SW, Wang X, Liu Y, Cheung YC, Feng H, Zheng Z, Wong N, Yuen PW, Lo AK, Wong YC, et al. (2002). Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. Biochim Biophys Acta 1590 (1-3), 150-158.
28. Li HM, Man C, Jin Y, Deng W, Yip YL, Feng HC, Cheung YC, Lo KW, Meltzer PS, Wu ZG, et al. (2006). Molecular and cytogenetic changes involved in the immortalization of nasopharyngeal epithelial cells by telomerase. Int J Cancer 119 (7), 1567-1576.
29. Jacobs JP, Jones CM, and Baille JP (1970). Characteristics of a human diploid cell designated MRC-5. Nature 227 (5254), 168-170.
30. Valent A, Benard J, Clausse B, Barrois M, Valteau-Couanet D, Terrier-Lacombe MJ, Spengler B, and Bernheim A (2001). In vivo elimination of acentric double minutes containing amplified MYCN from neuroblastoma tumor cells through the formation of micronuclei. Am J Pathol 158 (5), 1579-1584.
31. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, and Harran PG (2004). A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science 305 (5689), 1471-1474.
32. Rheinwald JG and Green H (1975). Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6 (3), 331-343.
33. Pioche-Durieu C, Keryer C, Souquere S, Bosq J, Faigle W, Loew D, Hirashima M, Nishi N, Middeldorp J, and Busson P (2005). In nasopharyngeal carcinoma cells, Epstein-Barr virus LMP1 interacts with galectin 9 in membrane raft elements resistant to simvastatin. J Virol 79 (21), 13326-13337.
34. Rodriguez SK, Keryer A, Drira C, Ghorbel M, Jlidi A, Bernehiem R, Valent A, and Busson P (2005). Conventional and array-based CGH analysis of nasopharyngeal carcinomas from the Mediterranean area: high frequency of gains at 1q and 12p and losses at 11q and 13q. Cancer Genet Cytogenet 157, 343-347.
35. Hui AB, Lo KW, Leung SF, Choi PH, Fong Y, Lee JC, and Huang DP (1996). Loss of heterozygosity on the long arm of chromosome 11 in nasopharyngeal carcinoma. Cancer Res 56 (14), 3225-3229.
36. Chang L, Kamata H, Solinas G, Luo JL, Maeda S, Venuprasad K, Liu YC, and Karin M (2006). The E3 ubiquitin ligase itch couples JNK activation to TNFalpha-induced cell death by inducing c-FLIP(L) turnover. Cell 124 (3), 601-613.
37. Letai AG (2008). Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 8 (2), 121-132.
38. Weinstein IB and Joe AK (2006). Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3 (8), 448-457.
39. Yip KW, Shi W, Pintilie M, Martin JD, Mocanu JD, Wong D, MacMillan C, Gullane P, O'Sullivan B, Bastianutto C, et al. (2006). Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin Cancer Res 12 (19), 5726-5732.
40. Iwakiri D, Sheen TS, Chen JY, Huang DP, and Takada K (2005). Epstein-Barr virus-encoded small RNA induces insulin-like growth factor 1 and supports growth of nasopharyngeal carcinoma-derived cell lines. Oncogene 24 (10), 1767-1773.
41. Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, Yun CO, and Choi KS (2007). Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin. Cancer Res 67 (17), 8274-8284.
42. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, and Lee TH (2000). Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 275 (24), 18022-18028.
43. Khabir A, Karray H, Rodriguez S, Rose M, Daoud J, Frikha M, Boudarawa T, Middeldorp J, Jlidi R, and Busson P (2005). EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in North African nasopharyngeal carcinomas. Virol J 2 (1), 39.